Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

• Status: Not yet recruiting
• Trial end date: 2020-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Azithromycin; Hydroxychloroquine; Inosine Pranobex; Levamisole

Criteria

Inclusion Criteria:

• Confirmed COVID 19 infection (positive PCR, elevated ESR, leucopenia)

• Clinical picture of COVID 19 infection including fever, malaise, sore throat, coughing, dyspnea, and runny nose

Exclusion Criteria:

• Mild cases of COVID 19 that do not require hospitalization

• Pregnant & lactating women

• Children with other comorbidities

• People who received previous treatment for COVID 19 in the last 2 weeks N.B. Diabetes and hypertension not excluded